DOV 102677

Drug Profile

DOV 102677

Alternative Names: DOV 102,677

Latest Information Update: 07 Sep 2010

Price : $50

At a glance

  • Originator DOV Pharmaceutical
  • Developer DOV Pharmaceutical; Euthymics Bioscience
  • Class Antidepressants
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine plasma membrane transport protein antagonists; Dopamine uptake inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alcoholism
  • Discontinued Major depressive disorder

Most Recent Events

  • 22 Jul 2010 Euthymics Bioscience acquires DOV Pharmaceutical
  • 17 Nov 2007 Phase-I development is ongoing
  • 12 Oct 2006 Discontinued - Phase-I for Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top